Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 29;14:146. doi: 10.1186/s13073-022-01151-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Neutralizing antibody levels in Delta and Omicron BA.1 breakthrough infections. a Box-violin plots of neutralizing antibody titers against Delta and Omicron subvariants compared to D614G, along with cumulative distribution function plots of titers against D614G, Delta, and Omicron subvariant (right), showing the proportion of samples at or above a given titer, in patients with Delta breakthrough infection. b Corresponding plots in patients with Omicron breakthrough infection using a pseudovirus neutralization assay. c Kernel density plot shows the distribution of collection days for samples from Delta and Omicron BA.1 breakthrough infections. All individuals with breakthrough infection in the study and available samples were collected 9–57 days after symptom onset or SARS-CoV-2 PCR test positivity when discharged from the hospital. d Box-violin plot showing pseudovirus-neutralizing antibody titers against D614G between Delta and Omicron BA.1 breakthrough infections. e Box-violin plot of pseudovirus-neutralizing antibody titers against D614G between asymptomatic or mild and moderate-severe breakthrough infections. For the box-violin plots, the median is represented by the thick black line inside the box. The geomatic mean titers (GMTs) are shown above each column for a, b, d, and e. The fold change of GMT is displayed in a and b. The horizontal dotted line represents the limit of detection of 30. A two-tailed Friedman test with a false discovery rate for multiple comparisons was performed to compare Delta and Omicron subvariants to D614G in a and b, and a two-tailed Wilcoxon rank-sum test was performed in c–e. p values are represented as ****p < 0.0001. No asterisk indicates no statistical significance